CCM
BEAM icon

Cinctive Capital Management’s Beam Therapeutics BEAM Stock Holding History

Cinctive Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,318
Closed -$397K – 376
2025
Q4 		$397K Buy
+14,318
New +$365K 0.02% 341
2025
Q1 		– Sell
-65,242
Closed -$1.62M – 328
2024
Q4 		$1.62M Buy
+65,242
New +$1.67M 0.08% 241

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Cinctive Capital Management's BEAM Position: Q1 2026 in Review

Cinctive Capital Management sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 14,318 shares — an estimated $397K sold.

Cinctive Capital Management first reported a position in BEAM in Q4 2024 and held it in 2 quarters. The position peaked at $1.62M in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Cinctive Capital Management reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 14,318 Beam Therapeutics shares in Q1 2026, an estimated $397K.
  • Cinctive Capital Management first reported a position in Beam Therapeutics in Q4 2024 and held it in 2 quarters.
  • Cinctive Capital Management's Beam Therapeutics position peaked at $1.62M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.